Chart-Typ:
Zeitraum:
| Pre-market Movers: IMCC, CVRX, TGTX, ROOT, PLTN. | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen |
| IM Cannabis Corp.: IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ET | TORONTO and GLIL YAM, Israel, May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations... ► Artikel lesen |
| IM Cannabis Corp.: IMC to transfer its Oranim Pharmacy shares back to the seller | TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel... ► Artikel lesen |
| Pre-market Movers: Treasure Global, Taysha Gene Therapies, PDD Holdings, SCWorx, Aquestive Therapeutics | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Treasure Global Inc. (TGL) is... ► Artikel lesen |
| Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Pivotal Study for Anaphylm (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting | Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are... ► Artikel lesen |
| Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm (epinephrine) Sublingual... ► Artikel lesen |
| Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen |
| Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal... ► Artikel lesen |
| Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | -- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq:... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
